D-0426-2024 Class II Terminated

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-0426-2024 was initiated by Amneal Pharmaceuticals Of New York, LLC on Dec 26, 2023 and is designated Class II. Reason for recall: Failed dissolution specifications The recall status is terminated (terminated Aug 16, 2024). Affected quantity: 21,452/100 count bottles.

Recall details

Product Type
Drugs
Report Date
Apr 3, 2024
Initiation Date
Dec 26, 2023
Termination Date
Aug 16, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
21,452/100 count bottles

Product description

Divalproex Sodium Extended-release Tablets, USP 250 mg, Rx Only, 100 tablets, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad, INDIA, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 65162-755-10. NDC# 65162-755-10

Reason for recall

Failed dissolution specifications

Distribution pattern

Product was distributed nationwide.

Code information

Lot # AR210704, exp. date 04/2024 AR210706, exp. date 04/2024 AR210707, exp. date 04/2024 AR210708, exp. date 04/2024 AR210709, exp. date 04/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0426-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0426-2024. Report a data issue: hello@regdatalab.com.